Therapeutic apheresis from the early civilizations to the twenty-first century;Aphérèse thérapeutique: des premières civilisations à nos jours

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 12, 2010, Pages 645-648

  Saniabadi, A R ^a   Hanai, H ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hamamatsu South Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADSORPTION; APHERESIS; CYTAPHERESIS; EDITORIAL; GRANULOCYTE; HISTORY OF MEDICINE; MONOCYTE; ULCERATIVE COLITIS;

BLOOD COMPONENT REMOVAL; COLITIS, ULCERATIVE; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HUMANS;

EID: 78649990528     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.09.003     Document Type: Editorial

References (22)

1. Goldfinger D., Capostagno V., Lowe C., Sacks H.J., Gatti R.A. Use of long-term leukapheresis in the treatment of chronic lymphocytic leukemia. Transfusion 1980, 20:450-454.
2. Eshleman J.R., Silberstein L.E. The development of selective plasmapheresis as a means for specific therapeutic intervention (editorial). Transfusion 1991, 31:96-98.
3. Hanai H., Watanabe F., Yamada M., Saniabadi A. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid dependent moderately severe ulcerative colitis. Digestion 2004, 70:36-44.
4. Clutterbuck H. On the proper administration of blood-letting for the prevention and cure of disease, London 1840. History & Special Collections. UCLA Louise M. Darling Biomedical Library.
5. Present D.H. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000, 6:48-57.
6. Cohen R.D. Treating ulcerative colitis without medications-" Look Mom No Drugs!" Gastroenterology 2005, 128:235-236.
7. Allison M.C., Dhillon A.P., Lewis W.G., Pounder R.E. Inflammatory bowel disease 1998, Mosby, London, p. 9-95.
8. Schreiber S., Nikolaus S., Hampe J. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999, 353:459-461.
9. Saniabadi A.R., Hanai H., Fukunaga K., Bjarnason I., Lofberg R. Therapeutic leucocytapheresis for inflammatory bowel disease. Transfus Apher Sci 2007, 37:191-200.
10. Hanai H., Watanabe F., Takeuchi K., Saniabadi A., Bjarnason I. Leukcocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol 2003, 1:28-35.
11. Rutgeerts P., Sandborn W.J., Hanauer S., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
12. Suzuki Y., Yoshimura N., Saniabadi A.R., Saito Y. Selective neutrophil and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004, 49:565-571.
13. Suzuki Y., Yoshimatsu Y., Saito Y., Saniabadi A. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006, 51:2031-2038.
14. Powrie F., Read S., Mottet C., Uhlig H., Maloy K. Control of immune pathology by regulatory T cells. Novartis Found Symp 2003, 252:92-98.
15. (High+)CD4 (+) and high pro-inflammatory CD28 (-)CD4 (+) T-cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007, 52:2725-2731.
16. Domenech E., Hinojosa J., Esteve-Comas M. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004, 20:1347-1352.
17. Maiden L., Takeuchi K., Baur R., Bjarnason I., O'Donohue J., Bjarnason I. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 2008, 14:1413-1418.
18. Muratov V., Lundahl J., Ulfgren A.K., Saniabadi A., Lofberg R. Downregulation of interferon-( parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease. A 12-month follow-up study. Int J Colorectal Dis 2006, 21:493-504.
19. Sands B.E., Sandborn W.J., Löfberg R., et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008, 135:400-409.
20. Tanaka T., Okanobu H., Murakami E., Kogame A., Imagawa H., Kuga Y. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naive patients. Dig Liver Dis 2008, 40:731-736.
21. Sakuraba A., Motoya S., Watanabe K., et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009, 104:2990-2995.
22. Probert C.S., Hearing S.D., Schreiber S., Kühbacher T., Ghosh S., Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52:998-1002.